Bangladesh
Tuberculosis profile
| High TB burden | High MDR-TB burden |
Population  2013 157 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 80 (51–110) 51 (33–69)
Mortality (HIV+TB only) 0.16 (0.1–0.24) 0.1 (0.07–0.15)
Prevalence  (includes HIV+TB) 630 (330–1 000) 402 (210–656)
Incidence  (includes HIV+TB) 350 (310–400) 224 (199–253)
Incidence (HIV+TB only) 0.41 (0.18–0.46) 0.26 (0.12–0.3)
Case detection, all forms (%) 53 (47–59)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.7–2.5) 29 (24–34)
MDR-TB cases among notified pulmonary
TB cases
2 100 (1 000–3 700) 2 600 (2 200–3 200)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 105 539   2 869
Pulmonary, clinically diagnosed 42 394   0
Extrapulmonary 33 704   0
       
Total new and relapse 184 506    
Previously treated, excluding relapses 6 385    
Total cases notified 190 891    
Among 181 637 new cases:
5 051 (3%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 446 (<1%) 4 611 (50%) 11 219
Laboratory-confirmed RR-/MDR-TB cases     1 024
Patients started on MDR-TB treatment     684
TB/HIV 2013 Number (%)
TB patients with known HIV status 2 067 (1)
HIV-positive TB patients 68 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 61 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 68 (100)
HIV-positive people screened for TB 607  
HIV-positive people provided with IPT 0  
Treatment success rate (%)
New and relapse cases registered in 2012 92
Previously treated cases, excluding relapse, registered in 2012 82
HIV-positive TB cases, all types, registered in 2012 81
RR-/MDR-TB cases started on second-line treatment in 2011 68
XDR-TB cases started on second-line treatment in 2011 100
Laboratories 2013  
Smear (per 100 000 population) 0.7
Culture (per 5 million population) <0.1
Drug susceptibility testing (per 5 million population) <0.1
Sites performing Xpert MTB/RIF 26
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 57
% Funded domestically 5%
% Funded internationally 33%
% Unfunded 62%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-04 Data: www.who.int/tb/data